Debt-to-equity of Mirum Pharmaceuticals, Inc. from 31 Mar 2020 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Mirum Pharmaceuticals, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2020 to 30 Sep 2025.
  • Mirum Pharmaceuticals, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 185%, a 4.1% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Mirum Pharmaceuticals, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 185% +7% +4.1% 30 Sep 2025
Q2 2025 191% +25% +15% 30 Jun 2025
Q1 2025 192% +4% +2.4% 31 Mar 2025
Q4 2024 188% +7% +3.6% 31 Dec 2024
Q3 2024 178% -4% -2.2% 30 Sep 2024
Q2 2024 166% -15% -8.5% 30 Jun 2024
Q1 2024 188% +49% +35% 31 Mar 2024
Q4 2023 181% +38% +26% 31 Dec 2023
Q3 2023 182% +40% +28% 30 Sep 2023
Q2 2023 181% +2% +1.4% 30 Jun 2023
Q1 2023 139% -38% -21% 31 Mar 2023
Q4 2022 143% -3% -1.8% 31 Dec 2022
Q3 2022 142% +36% +34% 30 Sep 2022
Q2 2022 179% +116% +182% 30 Jun 2022
Q1 2022 177% +142% +402% 31 Mar 2022
Q4 2021 146% +124% +575% 31 Dec 2021
Q3 2021 106% +93% +679% 30 Sep 2021
Q2 2021 63% +52% +457% 30 Jun 2021
Q1 2021 35% +21% +144% 31 Mar 2021
Q4 2020 22% 31 Dec 2020
Q3 2020 14% 30 Sep 2020
Q2 2020 11% 30 Jun 2020
Q1 2020 14% 31 Mar 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.